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Abstract
Introduction—Care of individuals with Alzheimer’s Disease and Related Dementias (ADRD) 
poses special challenges. As the disease progresses, individuals with ADRD require increasing 
levels of medical care, caregiver support, and long-term care which can lead to substantial 
economic burden.
Areas covered—In this expert review, we synthesized findings from studies of costs of ADRD 
in the United States that were published between January 2006 and February 2017, highlighted 
major sources of variation in costs, identified knowledge gaps and briefly outlined directions for 
future research and implications for policy and program planning.
Expert commentary—A consistent finding of all studies comparing individuals with and 
without ADRD is that the average medical, non-medical, and indirect costs of individuals with 
ADRD are higher than those without ADRD, despite the differences in the methods of identifying 
ADRD, duration of the study, payer type and settings of study population. The economic burden of 
ADRD may be underestimated because many components such as direct non-medical costs for 
home safety modifications and adult day care services and indirect costs due to the adverse impact 
of ADRD on caregivers’ health and productivity are not included in cost estimates.
Keywords
Dementia; alzheimer’s disease; economic burden; direct cost; indirect cost
CONTACT Kim Innes, kinnes@hsc.wvu.edu, Department of Epidemiology, West Virginia University, School of Public Health, Robert 
C. Byrd Health Sciences Center (North), Morgantown, WV 26506-9127, USA. 
Declaration of interest
KE Innes disclosure: NIH/NIGMS U54GM104942, Alzheimer’s Research and Prevention Foundation. JD Thornton disclosure: NIH 
Research Training Program in Behavioral and Biomedical Sciences 5 BBS T32 GM 081741-08. U Sambamoorthi disclosure: NIH/
NIGMS U54GM104942. The authors have no other relevant affiliations or financial involvement with any organization or entity with a 
financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
ORCID
Arijita Deb http://orcid.org/0000-0002-4570-0364(/p)(p)James Douglas Thornton http://orcid.org/0000-0001-6017-7500(/p)(p)Usha 
Sambamoorthi http://orcid.org/0000-0001-8311-1360(/p)(p)Kim Innes http://orcid.org/0000-0002-6395-7972
HHS Public Access
Author manuscript
Expert Rev Pharmacoecon Outcomes Res. Author manuscript; available in PMC 2018 April 
01.
Published in final edited form as:















Dementia is an umbrella term used to describe a level of neurocognitive impairment that can 
affect a person’s activities of daily living. Multiple etiologies, including Alzheimer’s disease 
(AD), vascular disease, presence of Lewy bodies, frontotemporal disease, and brain injury, 
can lead to dementia. Alzheimer’s disease and related dementias (ADRD) are generally 
characterized by progressive loss of memory and cognitive functioning; functional 
impairment in the performance of daily activities such as eating, making meals, bathing, and 
paying bills; and manifestation of neuropsychological symptoms such as depression, 
anxiety, agitation, apathy, delirium, and psychosis [1]. The most common cause of dementia 
among adults aged 65 years and older is AD that accounts for 60–80% of all dementias [2]. 
Other, less common forms of dementia are vascular dementia (VD), frontotemporal 
dementia (FTD), and Lewy body dementia (LBD) that comprise approximately 10%, 10%, 
and 4% of dementia cases, respectively [2,3]. It is expected that demographic shifts in the 
United States due to the rapid growth of the elderly population will increase the number of 
individuals afflicted with AD by threefold in the next 30 years [4].
As the disease progresses, individuals with ADRD require increasing levels of care and 
support, including medical treatment, prescription drugs, medical equipment, home safety 
modifications, safety services, personal care, adult day care, and, ultimately, full-time 
residential services. Currently, there is no cure for ADRD, and effective disease-modifying 
treatments remain elusive. Therefore, ADRD can impose a high financial burden on payers, 
patients and their families, health-care delivery systems, and society as a whole. According 
to recent estimates from the Alzheimer’s Association, the total direct medical expenditures 
associated with ADRD in the United States will increase from $236 billion in 2016 to more 
than $1 trillion in 2050 due to projected increases in the elderly population [2]. These figures 
do not take into account informal care and other indirect costs, including the unpaid care 
needed for those with ADRD and currently provided by almost 16 million Americans. For 
example, in 2015, unpaid caregivers provided approximately 18.1 billion hours of assistance, 
and this care has been valued conservatively at $221.3 billion [2].
With the rising economic burden of ADRD in the United States, it is important for health 
policy planners and other decision makers to gain a comprehensive understanding of the 
economic burden of AD/ADRD in the US population. In recent years, several studies have 
assessed the direct and indirect cost associated with ADRD [5–19]. Most studies have 
differed considerably in their definitions (AD/ADRD), data sources, cost estimation 
approaches, components of costs, and the stage at which costs were captured. A rigorous 
review and synthesis of studies that include both direct and indirect costs of AD/ADRD in 
the US population is lacking. In this critical review, we describe the various measures for 
assessing economic burden of ADRD, synthesize the findings from recent studies regarding 
costs of ADRD in the US population, highlighted major sources of variation in costs, 
identified knowledge gaps, and briefly outlined directions for future research and 
implications for policy and program planning.
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In this paper, we reviewed articles on direct and indirect costs of ADRD in the United States 
that were published in English between January 2006 and February 2017. To identify 
qualifying studies, we searched three scientific databases via EbscoHost (Medline, 
PsycINFO, and Web of Science) and scanned bibliographies of relevant review papers and 
identified articles. Search strings included different combination of the keywords ‘dementia,ʼ 
‘alzheimer*ʼ together with ‘economic,ʼ ‘expenditure,ʼ and ‘cost.ʼ One example of such a 
combination was (dementia OR alzheimer*) AND (‘economicʼ OR ‘expenditureʼ OR 
‘costʼ). Cost studies that did not target adults with ADRD, or did not include cost data, were 
excluded. We excluded conference abstracts, doctoral and master’s theses, and ‘gray’ 
literature. Of the 46 potentially relevant abstracts and citation indices scanned, 31 potentially 
eligible papers were identified for closer review. A total of 17 published articles met our 
eligibility criteria and were included in this review (Tables 1 and 2). Of these, nine studies 
[5–13] were on individuals with AD diagnosis, four studies [16,19–21] were on individuals 
with ADRD. These studies identified ADRD using International Classification of 
Diseases-9th edition clinical modification (ICD9-CM) codes for AD, VD, FTD, LBD, and 
unspecified dementias (senile dementia uncomplicated, senile dementia w/delusional or 
depressive features, senile dementia w/delusional features, senile dementia w/depressive 
features, dementia in conditions classified elsewhere, dementia in conditions classified 
elsewhere without behavioral disturbance, or senility w/o psychosis and presenile dementia) 
and four studies [14,15,17,18] were based on individuals with dementia identified using 
cognitive screening measures.
3. Identification of ADRD
One of the challenges in deriving precise estimates of costs of ADRD is the difficulty of 
identifying patients with ADRD. In the absence of specific biomarkers for differentiating the 
various subtypes of dementia, diagnosis of ADRD has remained essentially a clinical 
diagnosis based on patient’s cognitive and functional history, clinical examinations, and 
neuropsychological testing. As illustrated in Table 3, studies have used varying criteria and 
methods for defining ADRD. The most commonly used diagnostic criteria for identifying 
dementia are those detailed in the Diagnostic and Statistical Manual of Mental Disorders 
(DSM); these criteria were developed by the American Psychiatric Association and require 
(1) a continued gradual decline in memory function and (2) cognitive deficits in one or more 
domains which impair social and occupational functioning [23]. AD is often diagnosed 
using the National Institute on Neurological and Communicative Disorders and Stroke and 
the Alzheimer Disease and Related Disorders Association (NINCDS-ADRDA) criteria 
originally proposed in 1984 [24]. These criteria require a gradual and continued decline in 
two or more areas of cognition that is supported by clinical examination, neuroimaging tests, 
and cognitive screening tests such as Mini-Mental State Examination, Clinical Dementia 
Rating, Blessed Dementia Rating Scale, and other neuropsychological tests. Many registry-
based studies that have assessed the economic costs of AD have identified patients using the 
NINCDS-ADRDA criteria for ‘probable’ AD and/or the DSM-III-R or DSM-IV criteria 
[5,18,23–25].
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Alternatively, studies using the Health Retirement Survey (HRS), a nationally representative 
survey of adults aged 50 or older, determined probability of dementia with predictive 
modeling [14,15]. In these studies, probable dementia was identified using in-home clinical 
assessments on a sample of adults, and these data were then used to extrapolate ADRD 
prevalence in the population. However, given that these estimates are based in part on 
documented limitations in cognition and function, ADRD may be underestimated among 
individuals with mild symptoms/early stage disease.
In studies using the Medicare Current Beneficiary Survey (MCBS), a survey of nationally 
representative sample of beneficiaries enrolled in Medicare, ADRD has been determined 
using any of the three criteria: (1) self or proxy reports, (2) medications, and (3) the 
International Classification of Diseases-9th edition clinical modification (ICD9-CM) codes 
for ADRD [21] (Table 3). In other investigations relying on Medicare [20], Medicaid 
[16,26], and other commercial insurance claims databases [6,7], ADRD was likewise 
identified using the ICD9-CM codes recorded in inpatient, outpatient, skilled nursing home, 
and home health-care claims.
Limitations of most existing studies with respect to ADRD identification include lacking or 
inadequate information on ADRD severity as well as under diagnosis or misdiagnosis of 
ADRD leading to over or under estimation of costs. Claim-based studies use inpatient and 
outpatient claims to identify ADRD and do not have high sensitivity and specificity in 
identifying ADRD [27,28]. Therefore, there is potential to misclassify ADRD cases. In one 
study comparing the Medicare costs estimates for patients with ADRD to the costs of 
patients without ADRD, ADRD is identified in two different ways: one using Medicare 
claims and the other using clinical examinations [28]. Researchers reported that using 
Medicare claims resulted in substantial overestimation of the costs attributed to ADRD as 
compared to using clinical examinations to identify patients with ADRD [28]. In this study, 
using Medicare claims to identify ADRD was associated with a 110% increase in costs for 
those with ADRD as compared to a 68% increase when using clinical examinations to 
identify ADRD [28]. Similarly, a study using 5% Medicare claims data found that a 
considerable number of Medicare beneficiaries with VD or Parkinson’s dementia were 
misdiagnosed as AD, comprising almost 25% of reported AD cases [29]. Such misdiagnosis 
resulted in an incremental annual Medicare expenditure of $9500–$14,000 among the 
patients; this excess expenditure was largely eliminated after correcting for misdiagnoses 
[29]. Research has also shown that the chronology of AD diagnosis has substantial impacts 
on health-care costs. For example, patients who initially receive a diagnosis of cognitive 
impairment other than AD and are later diagnosed with AD incur significantly higher health-
care costs as compared to those who receive AD as their initial diagnosis [30].
4. Economic burden of ADRD: direct medical, nonmedical, and indirect 
costs
The economic burden of a disease is often assessed by measuring costs of the disease for 
society or part of society. Costs of a disease are typically grouped into direct and indirect 
costs. Direct medical costs of ADRD are associated with the use of resources for medical 
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care including hospital visits, physician visits, emergency department visits, pharmacy, and 
short-term skilled nursing facility care. Direct nonmedical costs include those associated, 
paid formal home-health care, transportation costs to health-care providers and costs of 
making necessary modifications to one’s diet, house, car, or related items. Indirect costs 
include costs due to premature death or loss of productivity, as well as costs of informal 
(unpaid) care.
4.1. Estimates and projections of national economic burden of ADRD
Estimates for the total direct medical costs of ADRD at the national level have been 
calculated by multiplying per capita cost estimates by the expected prevalence of ADRD in 
the population. For direct medical expenditures, the costs of care for prevalent ADRD in 
year 2010 in the United States were estimated as $109 billion [14]. Due to the accelerated 
aging of the population, this cost is projected to reach $259 billion by 2040, assuming that 
the current prevalence of ADRD and per capita direct medical cost of ADRD remain stable 
[14]. On the other hand, if recent declines in ADRD prevalence continue, estimated direct 
costs of prevalent ADRD would increase to only $154 billion by 2040, a more modest, but 
still substantial (70%) increase [31]. Thus, the broad variation in estimates of future direct 
costs of ADRD in part reflects differential assumptions regarding projected ADRD 
prevalence, cost of medical services for ADRD, and longevity of the population. As 
illustrated in the section on per-capita direct medical costs, variations in per-capita direct 
medical costs can also contribute to the variations in the national cost estimates.
In terms of indirect costs, the aggregate cost in 2010 for informal caregiving for ADRD in 
the United States was estimated at $159 billion dollars and $215 billion dollars using the 
forgone wage and replacement cost approach, respectively. This estimate exceeds the direct 
cost estimate of $109 billion in 2010 [14]. Assuming that the prevalence of ADRD remains 
constant at 2010 levels, these costs would increase to $379 billion and $511 billion, 
respectively, by 2040 [14]. Alternatively, using the same approach to valuing caregiver time 
but assuming a continued decline in ADRD prevalence, informal caregiving costs would 
increase to $226 and $305 billion, respectively, by 2040 [31].
4.2. Per-capita direct health-care costs of ADRD
In the United States, direct health-care costs are borne by insurers (both private and public) 
as well as by patients and their families. Currently, 68% of the total direct health-care costs 
of ADRD are covered by Medicare, a federal insurance program, and Medicaid, a federally 
subsidized insurance program administered by the states [2]. In 2015, Medicare spent an 
estimated $226 billion and Medicaid paid an estimated $44 billion on total direct health-care 
costs for individuals with ADRD [2]. The direct health-care costs can be further divided by 
the type of service such as inpatient visit, outpatient visit, physician office visit, pharmacy, 
emergency department, diagnostic and laboratory tests, long-term care, home care, and 
hospice care. For individuals with ADRD, long-term or nursing home care costs are a 
particularly critical component of total health-care costs.
The direct health-care costs of ADRD have typically been reported over variable time 
periods. These include prevalence-based costs, post-diagnosis costs, lifetime costs, and end-
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of-life costs. As costs of chronic conditions may follow a U-shape curve, peaking during the 
initial diagnosis and end-of-life periods, cost estimates may vary depending on at what stage 
the costs were captured.
4.2.1. Prevalence-based costs—The economic burden of ADRD has been measured 
using a snapshot of costs in 1 year known as the prevalence-based cost approach. Under this 
approach, costs are estimated for all individuals with ADRD in a given year (both incident 
and prevalent cases); such estimates are often used for budgetary allocations and for policy 
and program planning. In a study using HRS data, researchers reported that in 2010, the total 
per capita annual direct health-care costs of dementia were $28,501 [14]. Using the Medical 
Expenditures Panel Survey, community-dwelling adults over the age of 65 with ADRD had 
44% higher total health-care expenditures compared to patients without ADRD [19]. As can 
be seen from Table 1, there is a considerable variation in these costs based on the data 
sources, setting, and stage of ADRD.
4.2.2. Costs around the time of ADRD diagnosis—Nearly 30% of ADRD diagnoses 
occur during hospitalization for another serious condition such as cardiovascular disease, 
cerebrovascular diseases pneumonia, kidney disease, or infection [20]. Therefore, studies 
that focus on the immediate period after diagnosis can show higher costs (Table 1). 
Interestingly, studies assessing the direct medical costs around the time of ADRD diagnosis 
have shown that direct medical expenditures among individuals with ADRD were already 
significantly higher in the pre-diagnosis period than their non-ADRD counterparts perhaps 
due to diagnostic workup, early manifestations of cognitive impairment, and higher 
comorbidity burden (Table 1). In a recent study using 5% sample of Medicare claims, Lin et 
al. found that Medicare expenditures were 42% higher in the ADRD cohort in the 1-year 
pre-diagnosis period as compared to the matched non-ADRD cohort.
Following the diagnosis of ADRD, the Medicare expenditures increased 3 times within 1-
year and by 1.7 times by 2 years [30]. Similar pattern was observed in another study using 
Medicare Advantage Prescription Drug plan dataset. This study revealed that during the year 
prior to diagnosis of ADRD, total medical expenditures were 44% higher, 1 year after 
diagnosis, the total medical expenditures were 2 times higher, and 2 years after diagnosis, 
the total medical expenditures were 1.7 times higher in the AD versus non-AD cohort [12]. 
In addition, the perceptions of physicians, patients, and family members regarding ADRD 
may also affect health-care utilization following an ADRD diagnosis. Therefore, in a 
prospective multicenter study, researchers followed community dwelling Medicare 
beneficiaries at multiple centers in the northern Manhattan area of New York and clinically 
examined them to diagnose incident AD; however, both patients and their providers were 
blinded to the diagnosis of AD [18]. Nonetheless, Medicare expenditures were 65% higher 
in those diagnosed with AD than in those not diagnosed in the 2 years preceding diagnosis. 
After diagnosis, Medicare expenditures doubled in the AD cohort, whereas it only increased 
by 43% in the non-AD cohort.
4.2.3. End-of-life costs—Table 1 also presents end-of-life costs associated with ADRD. 
In a study using a prospective cohort of nursing home residents with advanced AD, Goldfeld 
et al. reported that the average total Medicare expenditures increased by 65% in the year 
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prior to death, with costs progressively increasing as death approached ($1061: 365–271 
days before death; $1605: 270–121 days before death; $2297: 120–91 days before death, 
and $3877: 90–0 days before death) [9]. The major drivers for end-of-life Medicare costs 
were hospitalizations (30.2%) and hospice care (45.6%) [9]. One retrospective cohort study 
using the HRS data assessed Medicare and Medicaid costs among patients with versus 
without dementia in the 5 years prior to death [15]. While there was no significant difference 
in the adjusted total Medicare spending in the dementia versus non-dementia group, average 
Medicaid spending was nearly 8 times higher in those with versus without ADRD [15]. 
Medicaid is the primary payer for long-term care for Medicaid eligible patients. Many 
patients who are not initially eligible for Medicaid may, after ‘spending down’ their assets, 
ultimately transition to Medicaid-supported long-term care. In contrast, Medicare does not 
support nursing home care, the major driver of end-of-life costs in adults with ADRD. Thus, 
it is not surprising that excess Medicare expenditures associated with ADRD are lower than 
excess Medicaid costs.
4.2.4. Life-time costs—Individuals with ADRD experience gradual declining health with 
an average life-expectancy of 8–10 years [32]. Cost estimates of ADRD may depend on the 
time during which costs are captured; therefore, it is important to estimate life-costs of 
ADRD [21]. As can be seen from Table 1, in a cohort-based simulation study assessed the 
lifetime costs of AD using the MCBS data. This study estimated the average lifetime 
Medicare expenditures using an estimated 5.1 year duration of dementia and found that the 
average lifetime Medicare expenditures was 13% higher ($101,810 vs. $89,835) and the 
average lifetime Medicaid expenditures was 69% higher ($27,028 vs. $15,955) per AD 
patient as compared to non-AD control group [21]. Not surprisingly, it was also reported that 
lifetime costs could be lowered with shorter duration of AD [21].
4.3. Type of direct health-care costs specific to ADRD
4.3.1. Formal home-health care costs—The unique characteristics of ADRD influence 
the drivers of direct health-care costs for ADRD. Due to the progressive decline in cognitive 
and functional status, many older patients with ADRD need home–health care and may 
spend their last years of life in long-term care facilities (Table 1). The annual number of paid 
home-health visits in the first year following ADRD diagnosis averaged 30 versus 13 among 
those without an ADRD diagnosis [20]. As the disease progresses, use of formal home-
health care use also increases. For example, in a prospective cohort study of elders with 
early stage AD at baseline, the percentage of patients receiving paid home health increased 
from 9.9% at the time of diagnosis to 34.5% by 4 years. The incremental total costs for paid 
home care in 2010 was $5678, accounting for 20% of the incremental direct costs associated 
with ADRD [14]. In one prospective study of Medicare beneficiaries, it was observed that 
excess costs of ADRD were largely due to home-health care, skilled nursing care, and 
durable medical equipment [18].
4.3.2. Nursing home costs—On average, individuals with mild-to-moderate ADRD 
aged between 70 and 80 years spend 3 years in a nursing home while those with severe 
ADRD spend 4 years in nursing home [33]. Therefore, a substantial portion of the direct 
costs associated with ADRD is for nursing home stays. In the United States, almost 75% of 
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the oldest adults with ADRD (≥80 years) are nursing home residents as compared to only 
4% of those without ADRD [33]. Therefore, it is not surprising that nursing home costs 
account for a major portion of the incremental total direct expenditures associated with 
ADRD [14]. For example, using HRS, a study reported that nursing home care costs 
accounted for 49% of the total direct medical costs of ADRD [14].
In the United States, Medicare does not cover long-term care stays; therefore, many ADRD 
patients rely on Medicaid to cover their long-term care expenditures. For example, in a 
retrospective cohort study of older Indiana Medicaid beneficiaries, 93% of the incremental 
Medicaid expenditures associated with ADRD were for nursing home stays [16]. Many 
ADRD patients required skilled nursing home care. It has been reported that during the year 
after diagnosis, skilled nursing home care costs were 9 times higher ($6755 vs. $727) 1 year 
after diagnosis in the ADRD cohort compared to no ADRD cohort [30].
4.4. Out-of-pocket spending by patients and their families
Although Medicare provides health-care coverage for most of the elderly in the United 
States, many elderly and their families pay for medical care out of their pockets. Out-of-
pocket spending includes spending on health insurance premiums, deductibles, coinsurance, 
and copayments for medical care and prescription drugs; certain services or equipment only 
partially covered or not covered by insurance; non-prescription medications; transportation 
to health-care providers; and uncovered structural or lifestyle modifications. According to 
the Global Health Observatory (GHO) data, out-of-pocket health-care expenditures by 
patients and/or their families comprised 45% of total health-care expenditures in 2014 [34]. 
Among Medicare beneficiaries, health insurance premiums account for 42% of the total out-
of-pocket spending, with payments toward cost-sharing and non-covered services and goods 
accounting for the remaining 58% [35]. It is important to assess the magnitude of out-of-
pocket expenditures because high out-of-pocket expenditures can also lead to worse health 
outcomes because of access issues. For example, individuals with high out-of-pocket costs 
may be more likely to stop taking their medications [36], less likely to use preventive care, 
and less likely to use outpatient services for their health care [37,38].
Estimation of out-of-pocket health-care expenditures burden is especially important for 
those with chronic conditions such as ADRD because these individuals may require long-
term medical care, residential services, and prescription drugs. Despite its importance, only 
few studies have evaluated out-of-pocket spending in the US population [13–15,39]. In an 
article not specific to ADRD, Hurd et al. examined average out-of-pocket spending among a 
nationally representative sample of older adults (HRS) with dementia [14]. In this study, out-
of-pocket spending included costs borne by the patient and the families for the following 
services: nursing home, hospital, medical visits, outpatient surgery, home-health care, 
rehabilitation, prescription drugs, and dental services. This study found that adults with 
dementia spent on the average $6838 out-of-pocket, an amount that was only slightly 
attenuated by adjustment for demographic factors and coexisting conditions (adjusted mean 
= $6194, 95% CI $4522, $7866). This figure may represent an underestimate because out-
of-pocket spending estimates did not include health insurance premiums and the study did 
not focus on those with ADRD [14]. Using data from the MCBS, it was estimated that 
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patients with ADRD and their families spent an average of $10,495 out-of-pocket for ADRD 
care, with those residing in long-term care facilities or assisted living facilities spending 6 
times as much as community dwelling patients with ADRD [2]. In another HRS study of 
decedents with likely/probable dementia, mean out-of-pocket costs for last 5 years of life 
totaled $61,522 for those with dementia and these individuals spent nearly 32% of their 
expenditures out-of-pocket [15]. Researchers using data from the nationally representative 
Aging, Demographics, and Memory Study found that individuals with dementia had more 
than 3 times annual out-of-pocket spending relative to those with normal cognition [39]. 
None of these studies examined out-of-pocket burden as measured by the percent of income 
spent on medical and nonmedical care.
As stated above, as many as three quarters of all patients with ADRD will require care in a 
long-term care facility [40]. Therefore, it is not surprising that individuals with ADRD spent 
a major proportion of their out-of-pocket costs on long-term care facilities [35]. Long-term 
facility costs account for much of the cost-sharing among Medicare beneficiaries who also 
qualified for Medicaid [41], suggesting that even with dual coverage of Medicare and 
Medicaid, individuals with ADRD face a significant financial burden.
High out-of-pocket expenditures can be borne not only by ADRD patients but also by their 
caregivers. These expenditures may include travel, medical supplies, food, and groceries. 
According to the Usage and Attitudes Family Caregiver Survey, nearly 50% of caregivers 
spent over $5000 annually [42]. Such expenditures can exact a toll on the caregivers by 
reducing their ability to pay for food, housing, health-care, and other basic needs and thus 
lead to significant declines in caregiver health and well-being [10,11,43].
4.5. Indirect costs
As stated above, another component of ADRD costs is the indirect costs that include costs 
due to loss of productivity as well as costs of informal (unpaid) care. Typically, indirect costs 
exclude costs specific to disease treatment [44]. In general, valuation of the productivity 
losses for elderly and specifically for patients with ADRD are scarce. As friends and family 
members provide nearly 75% of all caregiving for patients with ADRD [10,45], productivity 
loss is not limited to patients with ADRD but also affects informal caregivers who provide 
care for patients with ADRD [5,8,17]. As summarized in Table 2, in an epidemiological 
study using the HRS data, Friedman et al. reported that older adults with probable ADRD 
received 171 h of informal care per month versus 66 h for those without ADRD [46]. 
However, medical care provided by unpaid caregivers is not always included in costs 
estimations for ADRD.
The informal cost of care for ADRD is usually measured by valuing the time lost due to 
unpaid caregiving using the human capital approach. Initially, informal caregiving time is 
assessed in terms of caregiving hours per day or per week. Caregiving time is then valued in 
terms of either the replacement cost of hiring paid formal care or the opportunity cost due to 
lost wages (foregone wages). The former is measured by monetizing caregiving hours based 
on market wages paid to formal (paid) caregivers [13,14]; the latter is measured by valuing 
caregiving time in terms of the caregiver’s expected market wage based on the caregiver’s 
age, education, previous income, or occupation [5,8,14,15,17]. Details on data source, 
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informal cost estimation approach, wage estimates, and per capita cost estimates can be seen 
in Table 2.
Estimates of informal caregiving may vary depending on whether the replacement costs or 
the foregone wage approach is used. Using the same cohort of patients, average adjusted 
annual informal caregiving was valued at $13,188 (2010 USD) using the replacement costs 
approach and $27,789 (2010 USD) using the foregone wages approach by Hurd and 
colleagues in an analysis of the HRS data [14]. The foregone wage approach has been used 
in other studies to estimate informal caregiver costs (see Table 2) [5,8,15,17].
The estimate of indirect costs due to ADRD requires the consideration of factors other than 
productivity losses. Indirect ADRD costs need to include caregiver’s health-care resource 
utilization and health-care costs. It has been reported that members of households with AD 
patients were estimated to have significantly greater total annual medical, pharmacy, and 
total health-care costs than did those without AD patients [11]. For all caregivers of ADRD 




A consistent finding of all studies comparing individuals with and without ADRD is that the 
average medical, nonmedical, and indirect costs of individuals with ADRD are higher than 
those of individuals without ADRD [6,7,12,15,18–21], despite the differences in source of 
payment (Medicare, Medicaid, out-of-pocket), time period (lifetime vs. annual) and study 
population (e.g. decedents vs. all adults, AD vs. all forms of dementia), and stage of disease. 
Because of the long duration and the progressive cognitive and functional impairment 
characterizing ADRD, nursing home and home health-care services accounted for a 
substantial portion of the direct costs associated with ADRD. Nursing home stays, home 
health-care services, and informal caregiving accounted for more than three-fourth of the 
total costs associated with ADRD [14]. For community-dwelling individuals with ADRD, 
the indirect costs of ADRD far exceeded the direct costs of ADRD due to the high need for 
formal and informal caregiver services in these vulnerable populations [14,15]. In the United 
States, the combined direct and indirect costs of ADRD is higher than those of other serious 
chronic illnesses, including stroke, diabetes, heart disease, hypertension, lung disease, 
cancer, psychiatric problems, and arthritis in the US population [15].
5.2. Major sources of variation in costs
One important source of variation in the cost estimates stems from the differences in the 
method of determining ADRD across studies. Studies using administrative claims data such 
as Medicaid, Medicare, MarketScan, and PharMetrics have identified AD/ADRD based on 
diagnosed ADRD, whereas studies using survey data such as the HRS have assessed ADRD 
based on cognitive screening measures and registry-based studies have used clinical 
examinations to determine AD/ADRD. Studies that use claims data to identify ADRD at a 
particular point in time need to be particularly cautious in defining AD, because both 
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underreporting (mild cases) and misdiagnosis are common, potentially leading to inaccurate 
estimates of care costs for individuals with AD [28,29]. In addition, because the onset of AD 
is insidious, cognitive decline is typically gradual, and compensatory behaviors can mask 
early symptoms, capturing ‘true’ incident cases of AD can be challenging. The higher 
estimates of medical expenditures generated using claims based versus registry data likely 
reflect differences in stage of disease at diagnosis; while registries capture incident ADRD, 
claims data are more likely to reflect those with more advanced disease [18,20].
Other sources of variations in the cost estimates of studies are due to the determination of 
costs using approaches such as prevalence-based costs [14] versus incidence-based costs 
[20]. Studies that assessed annual costs of ADRD after incidence usually have higher 
estimates as compared to studies that have assessed costs using prevalence based approach. 
Other sources of variations in costs are due to the differences in the population setting 
(community vs. nursing home) and differences in the source of pay (Medicare, Medicaid, 
out-of-pocket).
6. Five-year view
6.1. Knowledge gaps and implications for future research
Direct nonmedical costs play a particularly important role in ADRD because as the disease 
progresses, home-safety modifications, safety services, personal care, adult day care, and 
full-time residential services are typically required [8,14]. Because studies generally do not 
include many of these costs, the cost burden of ADRD may be underestimated.
There remains a significant knowledge gap regarding estimation of indirect costs. Studies 
assessing the indirect costs of ADRD have primarily focused on the productivity loss or 
replacement cost of informal caregivers. However, caregiver burden is multidimensional 
[47]. Importantly, the chronic stressors associated with caregiving for ADRD patients can 
have significant adverse effects on caregiver health, increasing risk for depression, anxiety, 
hypertension, cardiovascular disease, dementia, and ultimately, mortality [48–51]. 
Therefore, to better capture the economic burden of ADRD, future studies need to measure 
loss in caregiver productivity, caregivers’ health, absenteeism, and employment. This 
information can help inform the development of programs and policies to more effectively 
address the burden of informal caregivers who provide care for ADRD patients.
Many studies have used insurance claims to estimate costs of ADRD. Claim-based databases 
are important because policy makers and payers also have developed new payment models 
(shared savings), performance evaluation (Centers for Medicare and Medicaid Services’s 
Star Rating System, National Quality Forum performance measures), payment reduction 
(e.g. 30-day readmissions for certain chronic conditions), and other policies to ensure high-
quality patient-centered care. With these shifts, administrative claims data have become vital 
to population health management. As most of the direct home health-care costs in the United 
States are borne by Medicare and most of the long-term care costs are borne by Medicaid, 
studies using only Medicare, Medicaid, or private insurance claims databases may 
underestimate the direct medical costs of care for ADRD.
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Therefore, to improve economic analysis of the direct and indirect costs of ADRD, efforts 
should be directed toward linking various registries of AD/ADRD and surveys with multiple 
administrative claims datasets from all payers. In this context, the all payer claims database 
(APCD) initiatives that are being implemented can offer great value for individuals covered 
by multiple health-care plans because of the industry-wide coding standards of health-care 
encounters. These databases will assist practitioners in patient care by providing a ‘360-
degree’ view of patients’ health care and ‘actionable intelligence’ that can offer specific 
guidance for improving chronic disease management. Indeed, use of health analytics 
involving large databases has been shown to bring about improvements such as increased 
adherence to guideline-based care, enhanced surveillance and monitoring, and decreased 
medication errors [52]. As of January 2016, 18 states have an APCD to help policy decision 
makers with cost containment and quality improvement strategies [53]. Unfortunately, 
establishment of APCDs has been met with resistance, and in 2015, the US Supreme Court 
ruled that self-insured group health plans are not required to comply with ACPD data 
requests [54]. Despite this setback, APCD implementation may not be significantly affected 
since many states have already received buy-in from these self-insured group health plans 
[55].
Additionally, long-term, prospective studies that track ADRD costs over time are needed 
because cost estimates can differ significantly based on ADRD severity. By helping to 
delineate the components, trajectories, and major drivers of costs and burden associated with 
ADRD from disease onset to end-of-life, findings from these studies will aid in program 
planning and help identify optimal timing for intervention.
6.2. Potential impact of emerging technology and treatment on ADRD burden
With the advances in neuroimaging technologies including volumetric magnetic resonance 
imaging, single-photon emission computed tomography, positron emission tomography 
imaging, cerebrospinal fluid beta, tau metabolites, and other serum markers, it may soon be 
possible to detect the ADRD at a prodromal or preclinical stage before the signs of the first 
clinical symptoms [56]. A recent predictive economic model has shown that the use of a 
neuroimaging technique for detection of early indicators of AD pathophysiology (with 90% 
sensitivity and specificity) and a disease modifying treatment that retards AD progression by 
50% would reduce the lifetime risk of AD in elderly adults from 10.5% to 5.7% [57]. 
Technological innovations for ADRD caregivers may reduce the caregiver burden. For 
example, intelligent assistive devices currently under development such as cognitive aids, 
environmental sensors, video and audio technologies to support daily life activities and 
monitor the safety of individuals with dementia have the potential to significantly reduce the 
burden of informal and formal caregiving for dementia [58].
7. Implications for future policy and program planning
The development and implementation of high impact policy and programs to reduce the 
escalating economic burden of ADRD requires a comprehensive understanding of the direct 
and indirect costs of ADRD throughout the disease trajectory. As long-term institutionalized 
care accounts for a significant portion of the federal and state spending on ADRD, policies 
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should be implemented to shift long-term care from institutional settings to home- and 
community-based settings [59]. This would necessitate implementation of new home- and 
community-based services and inclusion of such services in state Medicaid plans, as well as 
expansion of financial compensation programs for caregivers of patients with ADRD. 
Additionally, policy makers should facilitate the adoption of intelligent assistive devices and 
other technology-based services to reduce the burden on caregivers.
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• Identifying patients with ADRD is very challenging. Due to differences in 
diagnostic criteria and application, ascertainment and categorization of 
ADRD may vary across studies, leading to potential misclassification and 
inaccurate cost estimates.
• Despite the definitional differences, studies comparing patients with and 
without ADRD have consistently reported that the average medical, non-
medical, and indirect costs of individuals with ADRD were higher than those 
without ADRD.
• Nursing home costs and formal home-healthcare costs are the major 
contributors of the total direct costs of ADRD.
• Out-of-pocket expenditures on medical and non-medical services also impose 
a significant burden on patients and their caregivers. Yet there is no precise 
estimate of out-of-pocket expenditures burden as measured by income spent 
out-of-pocket.
• The overall economic burden of ADRD may be underestimated because many 
non-trivial components of costs such as direct non-medical costs and indirect 
costs are not included in the cost estimates.
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Table 3
Diagnostic definitions of Alzheimer’s diseases and related dementias used in cost of illness studies in the 
United States.
Studies Source AD/ADRD/Dementia Diagnostic definitions
Zhu, Scarmeas et 
al. [5], Zhu, 
Torgan et al. [8], 
Zhu, Scarmeas et 
al. [10]
Predictors Study AD Clinician-based diagnosis of:
 (1) Primary degenerative AD based on DSM-III-
R criteria,
 (2) Probable AD based on NINCDS-ADRDA 
criteria, and
 (3) Modified MMSE score of 30 or greater
Zhu, Cosentino et 
al. [18]
Washington Heights-Inwood Columbia 
Aging Project
AD Clinician-based diagnosis of:
 (1) Dementia based on DSM-IV criteria
 (2) Probable AD based on NINCDS-ADRDA 
criteria
Goldfeld, 
Stevenson et al. 
[9]
CASCADE study Dementia Clinician-based diagnosis of:
 (1) Cognitive Performance Score equal to 5 or 6,
 (2) Cognitive impairment due to dementia (any 
type),
 (3) Global Deterioration
 (4) Scale score of 7 ascertained by nurse 
interview, and
 (5) Length of NH stay >30 days
Murman, Eye et 
al. [25]
Neurology and geriatric medicine 
practices in the state of Michigan, USA
AD Clinician-based diagnosis of:
 (1) Probable AD based on the NINCDS-ADRDA 
criteria
Yang, Zhang et al. 
[21], Yang and 
Levey [13]
MCBS AD Based on
 (1) Self or proxy reported diagnosis of ADRD,
 (2) ICD-9-CM codes of 290 or 331.0, and
 (3) Self or proxy reported prescriptions for 
prescription for drugs including donepezil, 
rivastigmine, galantamine, and memantine
Hurd, Martorell et 
al. [14], Kelley, 
McGarry et al. 
[15]
Health and Retirement Study Dementia  (1) Probable dementia was determined based on 
an algorithm using multiple cognitive measures
Joyce, Zhao et al. 
[6]
PharMetrics Patient-Centric Database AD At least one claim with a diagnosis of AD (ICD.
9.CM 331.0)
Kuo, Zhao et al. 
[7]
MarketScan Medicare Supplemental and 
Coordination of Benefits Database
AD  (1) At least one claim with a diagnosis of AD 
(ICD.9.CM 331.0) and/or
 (2) At least one pharmacy claims for tacrine, 
donepezil, galantamine, rivastigmine, or memantine
Bharmal, Dedhiya 
et al. [16]
Medicaid claims Dementia At least one claim with any dementia-specific 
ICD-9 code (046.1, 290.0, 290.1x–290.4x, 291.2, 
294.1x, 331.0, 331.1x, 331.2, or 331.82)
Gilligan, Malone 
et al. [26]
Medicaid claims AD At least one claim with ICD-9 code of 331.0 in any 
section of the inpatient, long-term care, or 
outpatient Medicaid claim files
Suehs, Davis et al. 
[12], Suehs, Shah 
et al. [11]
Medicare Advantage Prescription Drug AD At least one claim with a diagnosis of AD (ICD.
9.CM 331.0)
Lin, Zhong et al. 
[20]
5% Medicare sample–claims ADRD ICD-9-CM codes of 331.0, 331.11, 331.19, 331.2, 
331.7, 290.0, 290.10, 290.11, 290.12, 290.13, 
290.20, 290.21, 290.3, 290.40, 290.41, 290.42, 
290.43, 294.0, 294.10, 294.11, 294.20, 294.21, 
294.8, 797
DSM: Diagnostic and Statistical Manual of Mental Disorders; ICD-9-CM: International Classification of Diseases, Ninth Revision, Clinical 
Modification; MMSE: Mini-Mental State Examination; NH: Nursing Home; NINCDS-ADRDA: National Institute of Neurological, 
Communicative Disorders and Stroke–Alzheimer Disease and Related Disorders Association; MCBS: Medicare Current Beneficiary Survey.
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